Krsnaa Diagnostics Limited · NSE:KRSNAA
Krsnaa Diagnostics — H1 FY2022 Earnings Presentation
29 slides from Krsnaa Diagnostics's earnings presentation, Oct 11, 2021
Slide 1: Krsnaa Diagnostics H1 FY2022 Earnings Presentation Cover Letter
0 Krsnad D I A G N O ST I CS'' LET'S DO GOOD... • Date: 11th October, 2021 BSE Limited The National Stock Exchange of India Limited Corporate Service Department, Exchange Plaza, 3 rd Floor, pt Floor, P. J. Towers, Plot No. C/1, 'G' Block, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai 400 00
Slide 2: H1 FY2022 Earnings Presentation
One of INDIA’S LARGEST Differentiated Diagnostic H1 FY2022 Earnings Presentation Service Provider www.krsnaadiagnostics.com
Slide 3: Business Overview
Business Overview DIAGNOSTICS® LETS D0 Gooo..*
Slide 4: Krsnaa Diagnostics at a Glance
Krsnaa Diagnostics at a Glance Fastest growing and differentiated diagnostic service provider in India 2011 Aug-21 1,800+ 14 States 23 Million Incorporated Listing at BSE Diagnostics Presence in India Patients Served and NSE Centre Since Inception Krsnaa Diagnostics is one of the fastest growing and
Slide 5: Krsnaa Diagnostics Edge
Krsnaa Diagnostics Edge One of the fastest growing diagnostic service provider in the country. Total Centre 1 count increased at a CAGR of 39% from 682 in FY18 to 1,803 in FY21 Extensive footprint and infrastructure across India with presence in 14 States. 2 Diagnostic equipment is state-of-the-art
Slide 6: Fastest Growing Diagnostic Chain In India
1. Fastest Growing Diagnostic Chain In India Fastest growing diagnostic chain in India, offering high quality services at disruptive prices Started operating 12 Pan India Expansion centres in Himachal Expansion Successful Pradesh in public Centres – 1,300+ Listing on the Centres – 664 private partne
Slide 7: Extensive Footprint and Infrastructure
2. Extensive Footprint and Infrastructure Radiology Centres Pathology Labs 128 44 CT Scans and MRI Processing Labs 1,242 443 X-Ray Tele-Reporting Collection Centres Centres 1,370 487 Radiology Centres Pathology Centres 6
Slide 8: Leading Radiology and Pathology Diagnostic Service Provider
2. Leading Radiology and Pathology Diagnostic Service Provider Krsnaa Diagnostics offers complete range of tests including 1,394 radiology tests and 2,544 pathological tests Radiology Segment Pathology Segment Rs. 1,619 mn | 41% Rs. 2,346 mn | 59% 1,365 | 75% 465 | 25% Radiology FY21 Revenue Patholo
Slide 9: Public Private Partnership – Industry Dynamics
3. Public Private Partnership – Industry Dynamics Diagnostic industry is underpenetrated in rural areas. Higher Government spend and initiatives is expected to drive PPP model faster than the overall diagnostic industry PPP Model is Backed by Government Initiatives Government Hospitals invite open b
Slide 10: Public Private Partnership Model Poised to Grow
4. Public Private Partnership Model Poised to Grow Krsnaa Diagnostic is the Partner for Public Health Agencies Track Record of Faster Expansion and Penetration in India ▪ 1,797 dedicated centres under PPP Model across 14 states ▪ 1,797 dedicated centres under PPP Model across 13 states Centers ▪▪ Sc
Slide 11: Partnership with Private Hospitals
4. Partnership with Private Hospitals Strategic Tie-ups with Private Health Players Private Centres Drives Brand Visibility and Brand Recall Centers ▪ Krsnaa Diagnostic is selectively entering into strategic tie-ups with leading Private Health Players 19% ▪ 26 centres under Private Model across 2 st
Slide 12: India's Largest Tele-Radiology Reporting Hub
4. India’s Largest Tele-Radiology Reporting Hub Krsnaa Diagnostics hub and spoke model radiology facility in Pune is fully capable to process large volumes ▪ Scalable business model and enables wider penetration into tier II and tier III cities Patient Report delivered to Entry ▪ Analog images gets
Slide 13: High Quality Diagnostic Services at Disruptive Prices
5. High Quality Diagnostic Services at Disruptive Prices Krsnaa offers radiology tests at 45%-60% lower and pathology tests at 40%-80% lower than market rates % from min Segment Test Player 1 Player 2 Player 3 Krsnaa price RDL CT Brain 4,500 4,500 3,500 2,000 (43%) “Krsnaa Diagnostics offers high qu
Slide 14: Defined Strategy to Deliver Sustainable Long Term Growth
6. Defined Strategy to Deliver Sustainable Long Term Growth Continue to Expand Presence Expand Diagnostic Services with Disciplined Acquisition to Expand across India Focus on Specialized Diagnostics Geographical Footprint Expand network within India, particularly in Pursue selective acquisitions an
Slide 15: H1 FY2022 Performance Update
H1 FY2022 Performance Update 14
Slide 16: H1 FY2022 Performance Highlights
H1 FY2022 Performance Highlights Krsnaa Diagnostics delivers stellar performance with Revenues of Rs. 241 Cr and EBITDA of Rs. 74 Cr with margins of 30.9% in H1 FY22 The growth was primarily driven by higher contribution from Core Business Core Business of Radiology and Pathology Rs. 2,407 Mn Rs. 74
Slide 17: H1 FY2022 Performance Highlights
H1 FY2022 Performance Highlights Revenue up by 19%, EBITDA1 up by 76% and PAT without CCPS2 is up by 167% Core business drives strong growth while Covid-19 contribution continues to decline ▪ Revenues up by 19%, primarily driven by growth in core business i.e Radiology and Pathology 11% which regist
Slide 18: Recent Developments
Recent Developments Krsnaa Diagnostics has recently won 5 PPP and private contracts to commission 29 CT Scanners and 8 MRI machines Punjab Radiology contract Himachal Pradesh Radiology contract 1 ▪ Punjab Government will allocate vacant space to establish 2 ▪ Hospitals in Solan and Bilaspur will pro
Slide 19: Management Perspective
Management Perspective Commenting on the results, Mr. Yash Mutha, Executive Director, said: “The year 2021 marks a significant milestone for Krsnaa Diagnostics in its growth story, as the company went public in August 2021. I would like to thank all our employees, partners and shareholders who have
Slide 20: Revenue and Segment Mix
Revenue and Segment Mix Revenue from Operations 19% Y-o-Y Revenue from Operations Breakdown 286 2,407 (75)% 2,027 929 1,502 1,154 1,325 237 1,083 921 50 192% 506 423 318 1,192 242 115% 582 610 556 339 Q2FY21 Q1FY22 Q2FY22 H1FY21 H1FY22 Q2FY21 Q1FY22 Q2FY22 H1FY21 H1FY22 Radiology Pathology COVID Seg
Slide 21: Profitability and Margins
Profitability and Margins Gross Profits and Margins 61% Y-o-Y EBITDA and Margins 76% Y-o-Y 744 1,492 431 420 424 925 324 721 819 673 48.0% 61.8% 62.1% 45.6% 62.0% 28.7% 31.7% 29.9% 30.9% 20.9% Q2FY21 Q1FY22 Q2FY22 H1FY21 H1FY22 Q2FY21 Q1FY22 Q2FY22 H1FY21 H1FY22 Profit Before Tax and without CCPS 16
Slide 22: Operational Performance Trend
Operational Performance Trend Core Business i.e Radiology and Pathology saw an increase in both, Number of Tests and Average Revenue Per Test in H1FY22 Decline in average revenue per patient and per test in H1 FY22 is due to significant decline in the prices of Covid-19 tests Number of Patient (in M
Slide 23: Operational Performance Trend
Operational Performance Trend Radiology and Pathology saw significant increase in both, Number of Tests and Average Revenue Per Test in H1FY22 NumberofofTests Number Tests(in (inMn) Mn) 104% Y-o-Y Average Revenue Per Test (in Rs) 0.66 5.31 1,860 1,980 0.12 0.54 0.58 440 434 0.50 3.05 411 2.17 223 2.
Slide 24: Segment Performance Trend
Segment Performance Trend Key Growth Drivers - Radiology and Pathology saw increase in its Revenue share with Covid-19 on a declining trend Tests Mix (Radiology, Pathology and Covid) Segment Revenue Mix 3% 8% 5% 18% 15% 15% 18% 11% 39% 61% 57% 39% 72% 38% 57% 68% 60% 63% 16% 16% 56% 44% 50% 22% 22%
Slide 25: Strengthening Balance Sheet
Strengthening Balance Sheet (Rs. Million) FY19 FY20 FY21 H1 FY22 • Krsnaa Diagnostics continues to strengthen Long Term Debt 920 1,227 1,680 362 its balance sheet with strong cash flow generation Short Term Debt 772 1,085 638 176 • Repaid Total Debt of Rs. 1,779 Mn in H1FY22 by Total Debt 1,692 2,31
Slide 26: Financial Performance
Financial Performance Q2 Y-o-Y Q1 Q-o-Q Six Months Y-o-Y Particulars (in Mn) FY2022 FY2021 Growth (%) FY2022 Growth (%) FY2022 FY2021 Growth (%) Core Business Revenues 1,033 581 77.9% 1,088 (5.0)% 2,121 873 142.9% Covid-19 Revenues 50 921 (94.6)% 237 (79.1)% 286 1,154 (75.2)% Revenue from Operations
Slide 27: Annual Performance Trend
Annual Performance Trend Revenue from Operations 64% CAGR Gross Profits and Margins 42% CAGR 3,965 2,045 2,584 1,552 2,092 1,296 51.6% 721 61.9% 60.0% 906 79.6% FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 Revenueand EBITDA fromMargins Operations 48% CAGR Profit Before Exceptional Items and CCPS 99% CAGR
Slide 28: Contact Information
Contact Information This presentation contains statements that are “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Krsnaa Diagnostics’ future business developments and economic perfor
Slide 29: Contact us: Krsnaa Diagnostics Ltd.
Contact us: Krsnaa Diagnostics Ltd. S.No.243,A-Hissa No.6/6 CTS No.4519, Near Mayur Trade Centre, Chinchwad, Pune, India - 411 019